Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors

BACKGROUND: Andexanet alfa is a modified recombinant inactive form of human factor Xa developed for reversal of factor Xa inhibitors. METHODS: We evaluated 352 patients who had acute major bleeding within 18 hours after administration of a factor Xa inhibitor. The patients received a bolus of andexa...

詳細記述

保存先:
書誌詳細
出版年:N Engl J Med
主要な著者: Connolly, Stuart J., Crowther, Mark, Eikelboom, John W., Gibson, C. Michael, Curnutte, John T., Lawrence, John H., Yue, Patrick, Bronson, Michele D., Lu, Genmin, Conley, Pamela B., Verhamme, Peter, Schmidt, Jeannot, Middeldorp, Saskia, Cohen, Alexander T., Beyer-Westendorf, Jan, Albaladejo, Pierre, Lopez-Sendon, Jose, Demchuk, Andrew M., Pallin, Daniel J., Concha, Mauricio, Goodman, Shelly, Leeds, Janet, Souza, Sonia, Siegal, Deborah M., Zotova, Elena, Meeks, Brandi, Ahmad, Sadia, Nakamya, Juliet, Milling, Truman J.
フォーマット: Artigo
言語:Inglês
出版事項: 2019
主題:
Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC6699827/
https://ncbi.nlm.nih.gov/pubmed/30730782
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1814051
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料